{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:49:42Z","timestamp":1782233382103,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anales de Pediatr\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.anpede.2026.504241","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:44:29Z","timestamp":1781300669000},"page":"504241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update and review of treatment in achondroplasia"],"prefix":"10.1016","volume":"104","author":[{"given":"Silvia","family":"Gallego-Guti\u00e9rrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Coral","family":"Barreda-Bonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isolina","family":"Ria\u00f1o-Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Leiva-Gea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Maria","family":"de Bergua-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Gal\u00e1n-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Leiva-Gea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anpede.2026.504241_bib0005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41574-021-00595-x","article-title":"International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia","volume":"18","author":"Savarirayan","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.anpede.2026.504241_bib0010","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1507\/endocrj.EJ24-0109","article-title":"Promising horizons in achondroplasia along with the development of new drugs","volume":"71","author":"Ozono","year":"2024","journal-title":"Endocr J"},{"key":"10.1016\/j.anpede.2026.504241_bib0015","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/ajmg.a.38853","article-title":"Growth in achondroplasia: development of height, weight, head circumference, and body mass index in a European cohort","volume":"176","author":"Merker","year":"2018","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.anpede.2026.504241_bib0020","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/s41436-021-01165-2","article-title":"Achondroplasia Natural History Study (CLARITY): a multicenter retrospective cohort study of achondroplasia in the United States","volume":"23","author":"Hoover-Fong","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.anpede.2026.504241_bib0025","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1507\/endocrj.EJ22-0477","article-title":"Assessment of body fat mass, anthropometric measurement and cardiometabolic risk in children and adolescents with achondroplasia and hypochondroplasia","volume":"70","author":"Nakano","year":"2023","journal-title":"Endocr J"},{"key":"10.1016\/j.anpede.2026.504241_bib0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2352-4642(23)00310-3","article-title":"New treatments for children with achondroplasia","volume":"8","author":"Savarirayan","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.anpede.2026.504241_bib0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000446958","article-title":"Height outcome of recombinant human growth hormone treatment in achondroplasia children: a meta-analysis","volume":"86","author":"Miccoli","year":"2016","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.anpede.2026.504241_bib0040","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00431-017-2923-y","article-title":"Final adult height in long-term growth hormone-treated achondroplasia patients","volume":"176","author":"Harada","year":"2017","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.anpede.2026.504241_bib0045","doi-asserted-by":"crossref","DOI":"10.1002\/ajmg.a.63612","article-title":"Clinical outcomes and medical management of achondroplasia in Japanese children: a retrospective medical record review of clinical data","volume":"194","author":"Saitou","year":"2024","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.anpede.2026.504241_bib0050","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.joca.2021.11.017","article-title":"Expanding horizons of achondroplasia treatment: current options and future developments","volume":"30","author":"Fafilek","year":"2022","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.anpede.2026.504241_bib0055","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1159\/000523868","article-title":"Novel treatment options in childhood bone diseases","volume":"96","author":"Jazbin\u0161ek","year":"2023","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.anpede.2026.504241_bib0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5582\/irdr.2023.01055","article-title":"Vosoritide, a miracle drug, covering unmet need in achondroplasia: a regulatory update","volume":"12","author":"Simran","year":"2023","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.anpede.2026.504241_bib0065","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1124\/jpet.114.218560","article-title":"Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism","volume":"353","author":"Wendt","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.anpede.2026.504241_bib0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJMoa1813446","article-title":"C-Type natriuretic peptide analogue therapy in children with achondroplasia","volume":"381","author":"Savarirayan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anpede.2026.504241_bib0075","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","article-title":"Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial","volume":"396","author":"Savarirayan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.anpede.2026.504241_bib0080","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/s41436-021-01287-7","article-title":"Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study","volume":"23","author":"Savarirayan","year":"2021","journal-title":"Genet Medi"},{"key":"10.1016\/j.anpede.2026.504241_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101274","article-title":"Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life","volume":"26","author":"Savarirayan","year":"2024","journal-title":"Genet Med"},{"key":"10.1016\/j.anpede.2026.504241_bib0090","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S2352-4642(23)00265-1","article-title":"Vosoritide therapy in children with achondroplasia aged 3\u221259 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"8","author":"Savarirayan","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.anpede.2026.504241_bib0095","first-page":"1","article-title":"Real-world safety and effectiveness of vosoritide in children with achondroplasia: French early access program","author":"Cormier-Daire","year":"2025","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.anpede.2026.504241_bib0100","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf041","article-title":"Real-world outcome of vosoritide treatment in children with achondroplasia: a 12-month retrospective observational study","volume":"9","author":"Reincke","year":"2025","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.anpede.2026.504241_bib0105","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1111\/bcp.15369","article-title":"Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug, TransCon CNP","volume":"88","author":"Breinholt","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.anpede.2026.504241_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102258","article-title":"Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"65","author":"Savarirayan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.anpede.2026.504241_bib0115","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/dvdy.642","article-title":"Infigratinib, a selective FGFR1-3 tyrosine kinase inhibitor, alters dentoalveolar development at high doses","volume":"252","author":"Michel","year":"2023","journal-title":"Dev Dyn"},{"key":"10.1016\/j.anpede.2026.504241_bib0120","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI83926","article-title":"Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model","volume":"126","author":"Komla-Ebri","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.anpede.2026.504241_bib0125","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/jbmr\/zjae051","article-title":"Low-dose infigratinib increases bone growth and corrects growth plate abnormalities in an achondroplasia mouse model","volume":"39","author":"Demuynck","year":"2024","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.anpede.2026.504241_bib0130","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221084848","article-title":"Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies","volume":"14","author":"Savarirayan","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.anpede.2026.504241_bib0135","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2411790","article-title":"Oral infigratinib therapy in children with achondroplasia","volume":"392","author":"Savarirayan","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anpede.2026.504241_bib0140","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.189307","article-title":"TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia","volume":"10","author":"Starrett","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.anpede.2026.504241_bib0145","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00774-024-01563-x","article-title":"Meclozine and growth hormone ameliorate bone length and quality in experimental models of achondroplasia","volume":"43","author":"Sawamura","year":"2025","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.anpede.2026.504241_bib0150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3171\/2016.7.PEDS16199","article-title":"Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia","volume":"19","author":"Matsushita","year":"2017","journal-title":"J Neurosurg Pediatr"},{"key":"10.1016\/j.anpede.2026.504241_bib0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0283425","article-title":"Phase 1b study on the repurposing of meclizine hydrochloride for children with achondroplasia","volume":"18","author":"Matsushita","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.anpede.2026.504241_bib0160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba4226","article-title":"An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice","volume":"13","author":"Kimura","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.anpede.2026.504241_bib0165","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006247","article-title":"Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice","volume":"5","author":"Garcia","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.anpede.2026.504241_bib0170","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/psp4.13143","article-title":"Natural disease course modeling of achondroplasia to evaluate the efficacy of recifercept in the absence of a placebo control arm in phase II study","volume":"13","author":"Qiao","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.anpede.2026.504241_bib0175","doi-asserted-by":"crossref","DOI":"10.1177\/00368504211003782","volume":"104","author":"Savarirayan","year":"2021","journal-title":"Sci Prog"},{"key":"10.1016\/j.anpede.2026.504241_bib0180","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1297\/cpe.29.25","article-title":"Clinical practice guidelines for achondroplasia","volume":"29","author":"Kubota","year":"2020","journal-title":"Clin Pediatric Endocrinol"},{"key":"10.1016\/j.anpede.2026.504241_bib0185","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.anpedi.2024.09.005","article-title":"Expert consensus for the management of patients with achondroplasia in treatment with vosoritide","volume":"101","author":"Barreda-Bonis","year":"2024","journal-title":"An Pediatr (Engl Ed)"},{"key":"10.1016\/j.anpede.2026.504241_bib0190","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1210\/clinem\/dgaf017","article-title":"Approach to the patient with achondroplasia - new considerations for diagnosis, management and treatment","volume":"110","author":"Merchant","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.anpede.2026.504241_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-024-03236-4","article-title":"International expert opinion on the considerations for combining vosoritide and limb surgery: a modified delphi study","volume":"19","author":"Boero","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.anpede.2026.504241_bib0200","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s13023-025-03853-7","article-title":"Intregrating vosoritide therapy with limb surgery in paediatric patients with achondroplasia: real-life experiences","volume":"20","author":"Allegri","year":"2025","journal-title":"Orphanet J Rare Dis"}],"container-title":["Anales de Pediatr\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2341287926001869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2341287926001869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:00:33Z","timestamp":1782230433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2341287926001869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2341287926001869"],"URL":"https:\/\/doi.org\/10.1016\/j.anpede.2026.504241","relation":{},"ISSN":["2341-2879"],"issn-type":[{"value":"2341-2879","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update and review of treatment in achondroplasia","name":"articletitle","label":"Article Title"},{"value":"Anales de Pediatr\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anpede.2026.504241","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.anpedi.2026.504241","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"504241"}}